1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19190
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFountzilas, G.en
dc.contributor.authorDafni, U.en
dc.contributor.authorGogas, H.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorStathopoulos, G. P.en
dc.contributor.authorKarina, M.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPisanidis, N.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorMarkopoulos, C.en
dc.contributor.authorTzorakoeleftherakis, E.en
dc.contributor.authorDimitrakakis, K.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorXiros, N.en
dc.contributor.authorPolichronis, A.en
dc.contributor.authorVarthalitis, I.en
dc.contributor.authorKaranikiotis, C.en
dc.contributor.authorDimopoulos, A. M.en
dc.date.accessioned2015-11-24T18:57:38Z-
dc.date.available2015-11-24T18:57:38Z-
dc.identifier.issn1569-8041-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19190-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAndrostadienes/administration & dosageen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/radiotherapy/surgeryen
dc.subjectCarcinoma/*drug therapy/radiotherapy/secondary/surgeryen
dc.subject*Chemotherapy, Adjuvanten
dc.subjectCombined Modality Therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDose-Response Relationship, Drugen
dc.subjectEpirubicin/administration & dosageen
dc.subjectEstrogensen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGranulocyte Colony-Stimulating Factor/therapeutic useen
dc.subjectHematologic Diseases/chemically induceden
dc.subjectHumansen
dc.subjectLymphatic Metastasisen
dc.subject*Mastectomyen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectNeoplasms, Hormone-Dependent/drug therapy/surgeryen
dc.subjectNeoplasms, Second Primary/epidemiologyen
dc.subjectPaclitaxel/administration & dosage/adverse effectsen
dc.subjectPeripheral Nervous System Diseases/chemically induceden
dc.subjectTamoxifen/administration & dosageen
dc.titlePostoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1093/annonc/mdm539-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18042835-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/19/5/853.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractBACKGROUND: A randomized phase III trial in high-risk breast cancer patients was conducted, to further explore the impact of dose-density in the adjuvant treatment for breast cancer. The safety analysis is presented. PATIENTS AND METHODS: From October 2000 until June 2005, 1121 node-positive patients were randomized to sequential dose-dense epirubicin 110 mg/m(2) and paclitaxel (Taxol, Bristol Myers-Squibb, Princeton, New Jersey, USA) 250 mg/m(2) (group A), or concurrent epirubicin 83 mg/m(2) and paclitaxel 187 mg/m(2) (group B), both followed by three cycles of 'intensified' combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF). Granulocyte colony-stimulating factor was given prophylactically with the dose-dense treatments. RESULTS: Median dose intensity of epirubicin and paclitaxel was double in group A, as designed, with significantly less cycles administered at full dose (P < 0.001). Median cumulative dose of all drugs and total treatment duration, however, were identical between groups. Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A. There were no differences in the rates of other hematological toxic effects, including febrile neutropenia. The rates of secondary malignancies were low. CONCLUSION: Both regimens as used in the present study are well tolerated and safe. The rates of severe taxane-related toxic effects and thrombocytopenia, although low overall, are significantly increased with the dose-dense sequential regimen.en
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Fountzilas-2008-Postoperative dose-d.pdf251 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons